ZGNX Zogenix, Inc.

12.90
+0.05  (0%)
Previous Close 12.85
Open 12.90
Price To book 3.15
Market Cap 320.09M
Shares 24,813,000
Volume 132,792
Short Ratio 13.64
Av. Daily Volume 202,821

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 initiation of efficacy portion announced February 13, 2017.
ZX008 - Study 1504
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Phase 3 data due 3Q 2017.
ZX008 - (Study 1)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
  2. ETFs with exposure to Zogenix, Inc. : May 11, 2017
  3. Edited Transcript of ZGNX earnings conference call or presentation 4-May-17 8:30pm GMT
  4. Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  5. Zogenix reports 1Q loss
  6. Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
  7. Investor Network: Zogenix, Inc. to Host Earnings Call
  8. Blog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome
  9. Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
  10. Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
  11. ETFs with exposure to Zogenix, Inc. : April 17, 2017
  12. Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  13. Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  14. Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
  15. Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
  16. Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
  17. Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome